Recurrent transverse myelitis in primary antiphospholipid syndrome—case report and literature review

Kim, J. H.; Lee, S. I.; Park, S. I.; Yoo, Wan‐Hee

doi:10.1007/s00296-003-0399-8

Cited by 26 publications

(15 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are scarce reports that link the presence of aPL with recurrent episodes of ATM [15–17]. Relapses during follow‐up (mean duration ± SD: 12.2 ± 7.7 months) were reported in 10% of cases and were not more frequent in aPL‐positive patients (Table 1).…”

Section: Discussionmentioning

confidence: 99%

Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation

Katsiari

Giavri

Mitsikostas

et al. 2010

European Journal of Neurology

View full text Add to dashboard Cite

Current views suggest that prothrombotic properties of antiphospholipid antibodies (aPL) have a role in the development of acute transverse myelitis (ATM) in patients with systemic lupus erythematosus (SLE). Consequently, empiric anticoagulation may be included in these patients' treatment. We performed a systemic review of the literature to explore the clinical value of the presence of aPL in patients with lupus myelitis and the possible effectiveness of anticoagulation. We analyzed clinical and laboratory data extracted from published cases of SLE-associated ATM, fulfilling the Transverse Myelitis Consortium Working Group diagnostic criteria, that provided information on aPL. We report on a total of 70 patients. aPL, detected upon ATM onset in 54% of patients, neither predicted the involvement of the thoracic part of the spine, which has been postulated to reflect a predominantly thrombosis-induced injury, nor correlated with relapsing ATM, additional lupus CNS manifestations, or worse clinical outcome. An unfavorable outcome could be predicted by paralysis (P=0.02) and abnormal CSF findings at presentation (P=0.02). Whilst all patients received major immunosuppressive regimens, severe neurologic impairment (estimated Expanded Disability Status Scale score>7) was found primarily in aPL-negative patients (P=0.03). Anticoagulation was more frequently applied in aPL-positive patients (P=0.04), but any additional therapeutic effect was not evident. Detection of circulating aPL at ATM onset appears unreliable to suggest a thrombotic cause and perhaps not enough to dictate therapeutic anticoagulation. Registry creation of ATM in patients with SLE is needed to obtain more definite answers on the role of aPL in this condition.

show abstract

Section: Discussionmentioning

confidence: 99%

Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation

Katsiari

Giavri

Mitsikostas

et al. 2010

European Journal of Neurology

View full text Add to dashboard Cite

show abstract

“…TM is an unusual complication of APS, with a prevalence of less than 1%. [91][92][93] Although typically monophasic, recurrent corticosteroid-responsive LETM has also been observed. 92 Characteristically, acute thoracic cord dysfunction occurs with sphincter involvement.…”

Section: Systemic Lupus Erythematosusmentioning

confidence: 99%

Transverse Myelitis

et al. 2013

View full text Add to dashboard Cite

Transverse myelitis (TM) includes a pathobiologically heterogeneous syndrome characterized by acute or subacute spinal cord dysfunction resulting in paresis, a sensory level, and autonomic (bladder, bowel, and sexual) impairment below the level of the lesion. Etiologies for TM can be broadly classified as parainfectious, paraneoplastic, drug/toxin-induced, systemic autoimmune disorders, and acquired demyelinating diseases. We discuss the clinical evaluation, workup, and acute and long-term management of patients with TM. Additionally, we briefly discuss various disease entities that may cause TM and their salient distinguishing features, as well as disorders that may mimic TM.

show abstract

“…Kim et al. [50] described a patient with recurrent attacks of transverse myelitis. The authors suggested that such attacks constitute a rare neurological complication of primary APS and that aPL play a critical role in the pathogenesis of transverse myelitis.…”

Section: Clinical Manifestationsmentioning

confidence: 99%

Neurological manifestations of antiphospholipid syndrome

Rodrigues¹,

Carvalho²,

Shoenfeld³

2010

Eur J Clin Investigation

104

View full text Add to dashboard Cite

Background Neurologic disorders are among the most common and important clinical manifestations associated with the antiphospholipid syndrome (APS). It is characterized by diverse neurological manifestations. These include stroke, transient ischaemic attack, Sneddon's syndrome, convulsions ⁄ epilepsy, dementia, cognitive deficits, headaches ⁄ migraine, chorea, multiple sclerosis-like, transverse myelitis, ocular symptoms and Guillain-Barré syndrome.

show abstract

Recurrent transverse myelitis in primary antiphospholipid syndrome—case report and literature review

Cited by 26 publications

References 9 publications

Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation

Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation

Transverse Myelitis

Neurological manifestations of antiphospholipid syndrome

Contact Info

Product

Resources

About